Patent application number | Description | Published |
20100233183 | CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE - The present invention concerns a molecule binding to LAG-3 protein and causing depletion of LAG-3′ activated T cells particularly said molecule is a cytotoxic anti-LAG-3 monoclonal antibody or fragment thereof. It also concerns a method of treating or preventing organ transplant rejection or autoimmune diseases in a mammal comprising administering to said mammal a therapeutically effective amount of said antibody. | 09-16-2010 |
20110070238 | CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE - Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3 | 03-24-2011 |
20110313135 | Recombinant Monovalent Antibodies - The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required. | 12-22-2011 |
20130058933 | MONOVALENT LIGANDS OF THE HUMAN CD28 RECEPTOR - The invention relates to monovalent ligands of the human CD28 receptor, which can selectively block the interaction between CD28 and B7 without activating the CD28 receptor. Said ligands can be used in particular in the production of immunosuppressant drugs, selectively blocking T lymphocyte activation phenomena involving the CD28 receptor. | 03-07-2013 |
20130078236 | Anti-CD28 humanized Antibodies - The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor. | 03-28-2013 |
20140308281 | ANTIBODIES DIRECTED AGAINST THE ALPHA CHAIN OF IL7 RECEPTOR - THEIR USE FOR THE PREPARATION OF DRUG CANDIDATES - The invention concerns antibodies directed against CD127, I.e. the alpha chain of the receptor for interleukin7 (IL-7), especially the receptor for human IL-7 expressed on human cells (designated human IL-7R alpha or IL-7Ra) or the TSLP receptor. The antibodies of the invention have cytotoxic activity against CD127 positive cells. The invention also relates to the use of these antibodies in order to deplete subpopulations of T lymphocytes as a result of cytotoxic action of the antibodies, through ADCC and optionally through CDC. Accordingly the invention concerns the use of the antibodies in the treatment of transplant rejection, autoimmune diseases, allergic diseases, lymphoma or cancer when these pathologies are associated with CD127 positive cells. | 10-16-2014 |
20150071916 | Anti-CD28 Humanized Antibodies - The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor. | 03-12-2015 |
Patent application number | Description | Published |
20110024429 | ASSEMBLY OF A CONTAINER AND A CLOSURE - An assembly of a container and a closure: the container having an outer shelf with a neck portion defining a first access opening and a flexible inner bag having a neck finish defining second access opening; the closure being fixed to the container, said closure having at least two access ports positioned in front of said access openings and; the assembly including a seal positioned between the closure and the container, wherein the seal has at least two distinct sealing members, one positioned between the closure and the neck portion, the other positioned between the closure and the neck finish. | 02-03-2011 |
20110024438 | ASSEMBLY OF A CONTAINER AND A CLOSURE - An assembly of a container and a closure, the assembly having an overpressure relief system, wherein the system has a fixation between the closure and a container, the fixation providing two positions in between which the closure is movable. | 02-03-2011 |
20110248035 | BAG-IN-CONTAINER WITH PREPRESSURIZED SPACE BETWEEN INNER BAG AND OUTER CONTAINER - Bag-in-container having an inner layer forming a bag filled with a fluid, the bag being separatable from an outer layer forming the container. The bag-in-container has a mouth fluidly connecting the volume defined by the bag to the atmosphere and separated therefrom by a seal. The container further having at least one space vent fluidly connecting the space between inner and outer layers and to the atmosphere. A vent provides a closure to control the gas flow between the space and the atmosphere. The space contains an amount of gas (V | 10-13-2011 |